IOL Chemicals and Pharmaceuticals posts Q1 FY25 PAT at Rs. 29.7 Cr
The company reported total income at Rs. 509.8 crore in Q1 FY25 as compared to Rs. 570.3 crore in Q1 FY24
The company reported total income at Rs. 509.8 crore in Q1 FY25 as compared to Rs. 570.3 crore in Q1 FY24
The pharma market is showing encouraging signs of improvement, positioning us well for future growth
The Gold Medal distinction places the company in the top 5% of all organizations assessed within EcoVadis's rigorous framework globally
The company recently received CEP certificate approval for Losartan Potassium by EDQM
Aarti Drugs has reported total income of Rs. 607.61 crores during the period ended December 31, 2023
The products are slated to be manufactured at the Ankleshwar facility and is expected to start contributing meaningfully to the revenue from FY25
This development is a strategic part of the company's commitment to bolstering its position in the advanced pharmaceutical intermediates segment
EBITDA for Q2 FY24 at Rs. 71.2 crore as compared to Rs. 79.9 crore QoQ
The product is expected to start contributing meaningfully to the revenue from FY25
Subscribe To Our Newsletter & Stay Updated